What are the age‑specific definitions, pathophysiology, and etiologies of hypoglycemia, and how should the evaluation and management of hypoglycemia—especially non‑ketotic hypoglycemia—be approached, including the relevant biochemical pathways?

Hypoglycemia: Age-Specific Definitions, Pathophysiology, Etiologies, and Approach

Age-Specific Definitions

Hypoglycemia is defined as plasma glucose <55 mg/dL (3.0 mmol/L) in adults when accompanied by symptoms, though some healthy women and children may have lower values during prolonged fasting without clinical significance 1.

Adults

• Symptomatic threshold: ~55 mg/dL (3.0 mmol/L) - where symptoms typically develop 1
• Action threshold in diabetes: ≤70 mg/dL (3.9 mmol/L) to allow time for intervention 1
• Critical threshold: <45 mg/dL (2.5 mmol/L) with symptoms warrants immediate evaluation 1

Neonates and Children

The definition varies by age and clinical context 2, 3:

• Neonates: More permissive thresholds initially, but persistent values <50 mg/dL require investigation
• Infants/Children: Similar to adults (~55 mg/dL with symptoms), though healthy children may tolerate lower values during prolonged fasting 1
• Important caveat: Decision to end diagnostic fasting should not be based solely on low glucose without symptoms, as healthy women and children can have physiologically low values 1

---

Pathophysiology

Hypoglycemia develops when glucose utilization exceeds glucose delivery into circulation, typically from inadequate hepatic/renal glucose production or excessive glucose consumption 1.

Normal Glucose Homeostasis

The brain requires continuous glucose supply (cannot synthesize glucose or effectively use alternative fuels under physiological conditions) 1. Blood-to-brain glucose transport is directly proportional to arterial plasma glucose concentration.

Counterregulatory Defense Mechanisms (in order of activation):

1. Decreased insulin secretion - occurs as glucose declines within physiological range
2. Increased glucagon secretion - activates as glucose falls just below physiological range
3. Increased epinephrine secretion - backup mechanism when glucagon fails
4. Increased cortisol and growth hormone - involved in defense against prolonged hypoglycemia 1

At glucose ≤55 mg/dL, insulin secretion is virtually completely suppressed (insulin <3 µU/mL, C-peptide <0.6 ng/mL, proinsulin <5.0 pmol/L) 1.

Biochemical Basis

Glucose utilization occurs primarily by:

• Brain (obligate consumer)
• Obligatory glycolytic tissues (renal medullae, erythrocytes)
• Insulin-sensitive tissues (muscle) 1

Glucose delivery comes from:

• Ingested carbohydrates
• Hepatic glucose production (glycogenolysis and gluconeogenesis)
• Renal glucose production 1

---

Age-Specific Etiologies

Adults (Non-Diabetic)

Drugs are the most common cause of hypoglycemia in adults 1:

• Insulin and insulin secretagogues (sulfonylureas, meglitinides)
• Alcohol (inhibits gluconeogenesis)
• Other medications (quinolones, pentamidine, quinine)

Other major causes:

• Critical illnesses: Sepsis, renal failure, hepatic failure 1
• Hormone deficiencies: Cortisol deficiency, growth hormone deficiency 1, 4
• Endogenous hyperinsulinism: Insulinoma (rare) 1
• Non-islet cell tumors: Produce IGF-II 1
• Post-bariatric surgery: Particularly post-gastric bypass, can be insulin-mediated or non-insulin-mediated 4
• Factitious hypoglycemia: Surreptitious insulin or sulfonylurea use 1

Neonates and Children

The etiology spectrum differs significantly from adults 2, 3, 5:

Neonatal period:

• Transitional hypoglycemia (most common)
• Congenital hyperinsulinism
• Perinatal stress/asphyxia
• Maternal diabetes
• Inborn errors of metabolism

Infants and children:

• Idiopathic ketotic hypoglycemia (most common in children 18 months-5 years) 5
• Congenital hyperinsulinism 3
• Glycogen storage disorders 3, 6
• Fatty acid oxidation defects 3, 6
• Hormone deficiencies: Cortisol, growth hormone 3, 5
• Other inborn errors of metabolism: Amino acid disorders, organic acidemias 6

---

Approach to Hypoglycemia Evaluation

Initial Assessment

Begin by determining if the patient has diabetes or is seemingly well versus critically ill 1. This fundamentally changes the diagnostic approach.

For non-diabetic patients, the Endocrine Society recommends a systematic strategy 1:

Step 1: Review for Obvious Causes

Examine history, physical findings, and laboratory data for:

• Medications (especially insulin, sulfonylureas, alcohol)
• Critical illnesses (sepsis, organ failure)
• Hormone deficiencies (look for signs of adrenal insufficiency, hypopituitarism)
• Non-islet cell tumors (large mesenchymal or epithelial tumors)

Step 2: Document Whipple's Triad During Spontaneous Episode

When cause is not evident, obtain during symptomatic hypoglycemia 1:

• Plasma glucose (laboratory-measured, not point-of-care)
• Insulin
• C-peptide
• Proinsulin
• β-hydroxybutyrate
• Screen for oral hypoglycemic agents
• Insulin antibodies
• Glucagon stimulation test: Inject 1.0 mg IV glucagon, measure glucose at 10,20,30 minutes

Step 3: Provocation Testing if Spontaneous Episode Cannot Be Observed

72-Hour Supervised Fast (for suspected fasting hypoglycemia) 1:

• Discontinue all non-essential medications
• Allow calorie-free beverages only
• Patient must be active during waking hours
• Measure glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate every 6 hours initially
• When glucose <60 mg/dL, increase sampling to every 1-2 hours
• End fast when: Glucose <45 mg/dL with symptoms OR glucose <55 mg/dL if Whipple's triad previously documented OR 72 hours elapsed
• At end: Obtain all samples above plus glucagon stimulation test

Mixed-Meal Test (for suspected postprandial hypoglycemia) 1:

• After overnight fast
• Use meal similar to what provokes symptoms (or commercial formula)
• Sample glucose, insulin, C-peptide, proinsulin before and every 30 minutes through 300 minutes
• Document symptoms with timing
• Send insulin/C-peptide/proinsulin only if glucose <60 mg/dL

---

Approach to Non-Ketotic Hypoglycemia with Biochemical Pathways

Non-ketotic hypoglycemia indicates insulin or insulin-like factor excess, as insulin suppresses ketogenesis 1.

Biochemical Framework

Normal Fasting Metabolism

During fasting, as glucose falls:

1. Insulin secretion decreases → allows lipolysis
2. Free fatty acids released from adipose tissue
3. Fatty acids undergo β-oxidation in liver mitochondria
4. Acetyl-CoA produced → converted to ketone bodies (β-hydroxybutyrate, acetoacetate)
5. Ketones serve as alternative fuel for brain during prolonged fasting

Non-Ketotic Hypoglycemia Pathway Disruption

When insulin is elevated (inappropriately for glucose level):

• Lipolysis is suppressed → decreased free fatty acid release
• Fatty acid oxidation is inhibited → reduced acetyl-CoA production
• Ketogenesis is blocked → β-hydroxybutyrate remains low (≤2.7 mmol/L) 1
• Glycogen stores are depleted but gluconeogenesis is also suppressed
• Result: Hypoglycemia without compensatory ketone production

Diagnostic Interpretation

Endogenous hyperinsulinemic hypoglycemia is documented by 1:

• Glucose <55 mg/dL (3.0 mmol/L) with symptoms
• Insulin ≥3.0 µU/mL (18 pmol/L) - inappropriately elevated
• C-peptide ≥0.6 ng/mL (0.2 nmol/L) - confirms endogenous insulin
• Proinsulin ≥5.0 pmol/L
• β-hydroxybutyrate ≤2.7 mmol/L - suppressed ketogenesis
• Glucose increase ≥25 mg/dL after IV glucagon - indicates glycogen stores present

Differential Diagnosis of Non-Ketotic Hypoglycemia

Insulin-mediated causes:

1. Endogenous insulin excess:

   • Insulinoma: Autonomous insulin secretion from pancreatic β-cell tumor
   • Nesidioblastosis: Diffuse β-cell hyperplasia (rare in adults)
   • Post-gastric bypass hypoglycemia: β-cell hyperresponsiveness
   • Insulin autoimmune syndrome: Insulin antibodies cause erratic insulin release

2. Exogenous insulin:

   • Factitious hypoglycemia: Surreptitious insulin injection
     • High insulin, low C-peptide (distinguishes from endogenous)
     • Screen for insulin antibodies (may be present with exogenous insulin)

3. Sulfonylurea/meglitinide use:

   • Stimulates endogenous insulin secretion
   • High insulin, high C-peptide
   • Positive drug screen differentiates from insulinoma

IGF-mediated causes:

• Non-islet cell tumor hypoglycemia: Large tumors produce IGF-II
  • Low insulin, low C-peptide
  • But still non-ketotic (IGF-II has insulin-like effects)
  • Suppressed IGF-I, elevated IGF-II:IGF-I ratio

Biochemical Pathways in Specific Disorders

Insulinoma Pathway

Autonomous β-cell tumor
↓
Continuous insulin secretion (independent of glucose)
↓
Suppresses: Lipolysis → Ketogenesis
           Glycogenolysis (eventually depleted)
           Gluconeogenesis
↓
Hypoglycemia + Low ketones + Glycogen stores present (positive glucagon response)

Fatty Acid Oxidation Defects (Ketotic Hypoglycemia for Comparison)

Defect in β-oxidation enzymes (e.g., MCAD deficiency)
↓
Cannot oxidize fatty acids → No acetyl-CoA production
↓
No ketone body formation despite low insulin
↓
Hypoglycemia + Low/absent ketones BUT low insulin (distinguishes from hyperinsulinism)

Localization After Diagnosis

Once endogenous hyperinsulinemic hypoglycemia is confirmed (negative drug screen, no insulin antibodies), localize insulinoma 1:

• CT or MRI of pancreas
• Transabdominal ultrasound
• Endoscopic ultrasound (most sensitive for small tumors)
• Selective arterial calcium stimulation with hepatic venous insulin sampling (if imaging negative but biochemistry diagnostic)

---

Critical Pitfalls to Avoid

1. Do not rely on point-of-care glucose monitors for diagnostic decisions - use laboratory-measured plasma glucose 1

2. Do not end diagnostic fast based solely on low glucose without symptoms in women or children - they may have physiologically low values 1

3. Do not diagnose "reactive hypoglycemia" based on symptoms alone without documented Whipple's triad - this represents a functional disorder, not true hypoglycemia 1

4. Do not forget to measure β-hydroxybutyrate - this is critical for distinguishing insulin-mediated from non-insulin-mediated hypoglycemia 1

5. Always screen for exogenous hypoglycemic agents before pursuing expensive localization studies for insulinoma 1

6. Measure C-peptide with insulin - low C-peptide with high insulin indicates exogenous insulin (factitious hypoglycemia) 1

7. In children with short stature and recurrent hypoglycemia, consider growth hormone deficiency even in post-bariatric patients 4

8. In post-bariatric patients, consider both insulin-mediated and non-insulin-mediated causes including hormonal deficiencies 4